PMC:7195088 / 61792-63641
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 1859 | 930-948 | Gene | denotes | C-reactive protein | Gene:1401 |
| 1860 | 1315-1319 | Gene | denotes | IL-6 | Gene:3569 |
| 1861 | 1645-1649 | Gene | denotes | IL-6 | Gene:3569 |
| 1862 | 164-172 | Species | denotes | patients | Tax:9606 |
| 1863 | 256-264 | Species | denotes | patients | Tax:9606 |
| 1864 | 622-630 | Species | denotes | patients | Tax:9606 |
| 1865 | 1271-1279 | Species | denotes | patients | Tax:9606 |
| 1866 | 1830-1838 | Species | denotes | patients | Tax:9606 |
| 1867 | 0-11 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 1868 | 389-400 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1869 | 636-647 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1870 | 1096-1107 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1871 | 1167-1178 | Chemical | denotes | Tocilizumab | MESH:C502936 |
| 1872 | 1577-1588 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1873 | 1806-1817 | Chemical | denotes | tocilizumab | MESH:C502936 |
| 1874 | 178-198 | Disease | denotes | rheumatoid arthritis | MESH:D001172 |
| 1875 | 200-220 | Disease | denotes | giant-cell arteritis | MESH:D013700 |
| 1876 | 222-251 | Disease | denotes | juvenile idiopathic arthritis | MESH:D001171 |
| 1877 | 613-621 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1878 | 1292-1300 | Disease | denotes | COVID-19 | MESH:C000657245 |
| 1879 | 1821-1829 | Disease | denotes | COVID-19 | MESH:C000657245 |
LitCovid-PD-FMA-UBERON
| Id | Subject | Object | Predicate | Lexical cue | fma_id |
|---|---|---|---|---|---|
| T97 | 50-58 | Body_part | denotes | antibody | http://purl.org/sig/ont/fma/fma62871 |
| T98 | 97-99 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T99 | 206-210 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T100 | 298-302 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
| T101 | 338-346 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T102 | 423-431 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T103 | 463-471 | Body_part | denotes | cytokine | http://purl.org/sig/ont/fma/fma84050 |
| T104 | 776-780 | Body_part | denotes | body | http://purl.org/sig/ont/fma/fma256135 |
| T105 | 821-826 | Body_part | denotes | blood | http://purl.org/sig/ont/fma/fma9670 |
| T106 | 876-886 | Body_part | denotes | lymphocyte | http://purl.org/sig/ont/fma/fma62863 |
| T107 | 941-948 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
| T108 | 1315-1317 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
| T109 | 1645-1647 | Body_part | denotes | IL | http://purl.org/sig/ont/fma/fma86578 |
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T50 | 821-826 | Body_part | denotes | blood | http://purl.obolibrary.org/obo/UBERON_0000178 |
LitCovid-PD-HP
| Id | Subject | Object | Predicate | Lexical cue | hp_id |
|---|---|---|---|---|---|
| T103 | 178-198 | Phenotype | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/HP_0001370 |
| T104 | 211-220 | Phenotype | denotes | arteritis | http://purl.obolibrary.org/obo/HP_0012089 |
| T105 | 222-251 | Phenotype | denotes | juvenile idiopathic arthritis | http://purl.obolibrary.org/obo/HP_0005681 |
| T106 | 338-363 | Phenotype | denotes | cytokine release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
| T107 | 423-448 | Phenotype | denotes | cytokine release syndrome | http://purl.obolibrary.org/obo/HP_0033041 |
LitCovid-PD-MONDO
| Id | Subject | Object | Predicate | Lexical cue | mondo_id |
|---|---|---|---|---|---|
| T361 | 178-198 | Disease | denotes | rheumatoid arthritis | http://purl.obolibrary.org/obo/MONDO_0008383 |
| T362 | 189-198 | Disease | denotes | arthritis | http://purl.obolibrary.org/obo/MONDO_0005578 |
| T363 | 200-220 | Disease | denotes | giant-cell arteritis | http://purl.obolibrary.org/obo/MONDO_0008538 |
| T364 | 211-220 | Disease | denotes | arteritis | http://purl.obolibrary.org/obo/MONDO_0043494 |
| T365 | 222-251 | Disease | denotes | juvenile idiopathic arthritis | http://purl.obolibrary.org/obo/MONDO_0011429 |
| T366 | 242-251 | Disease | denotes | arthritis | http://purl.obolibrary.org/obo/MONDO_0005578 |
| T367 | 613-621 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T368 | 1292-1300 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
| T369 | 1821-1829 | Disease | denotes | COVID-19 | http://purl.obolibrary.org/obo/MONDO_0100096 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T336 | 15-16 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T337 | 29-38 | http://purl.obolibrary.org/obo/NCBITaxon_9606 | denotes | humanized |
| T338 | 70-78 | http://purl.obolibrary.org/obo/UBERON_0000158 | denotes | membrane |
| T339 | 206-210 | http://purl.obolibrary.org/obo/GO_0005623 | denotes | cell |
| T340 | 296-302 | http://purl.obolibrary.org/obo/CL_0000084 | denotes | T-cell |
| T341 | 532-533 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T342 | 568-570 | http://purl.obolibrary.org/obo/CLO_0054055 | denotes | 71 |
| T343 | 670-674 | http://purl.obolibrary.org/obo/CLO_0008416 | denotes | peer |
| T344 | 670-674 | http://purl.obolibrary.org/obo/CLO_0050081 | denotes | peer |
| T345 | 760-761 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T346 | 809-810 | http://purl.obolibrary.org/obo/CLO_0001021 | denotes | b |
| T347 | 821-826 | http://purl.obolibrary.org/obo/UBERON_0000178 | denotes | blood |
| T348 | 821-826 | http://www.ebi.ac.uk/efo/EFO_0000296 | denotes | blood |
| T349 | 1179-1182 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T350 | 1239-1240 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T351 | 1442-1443 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T352 | 1484-1485 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T353 | 1589-1592 | http://purl.obolibrary.org/obo/CLO_0051582 | denotes | has |
| T354 | 1637-1638 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-PD-CHEBI
| Id | Subject | Object | Predicate | Lexical cue | chebi_id |
|---|---|---|---|---|---|
| T15169 | 97-99 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T52655 | 279-286 | Chemical | denotes | antigen | http://purl.obolibrary.org/obo/CHEBI_59132 |
| T41669 | 389-400 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T61099 | 636-647 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T28602 | 731-742 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T88075 | 941-948 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
| T73 | 1096-1107 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T72663 | 1315-1317 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T84369 | 1577-1588 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
| T38193 | 1645-1647 | Chemical | denotes | IL | http://purl.obolibrary.org/obo/CHEBI_63895|http://purl.obolibrary.org/obo/CHEBI_74072 |
| T71139 | 1806-1817 | Chemical | denotes | tocilizumab | http://purl.obolibrary.org/obo/CHEBI_64360 |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T448 | 0-372 | Sentence | denotes | Tocilizumab is a recombinant humanized monoclonal antibody inhibiting membrane-bound and soluble IL-6 receptors [68] and is currently approved for the treatment of patients with rheumatoid arthritis, giant-cell arteritis, juvenile idiopathic arthritis and patients with chimeric antigen receptor T-cell–induced severe or life-threatening cytokine release syndrome [68,69]. |
| T449 | 373-528 | Sentence | denotes | In this regard, tocilizumab may help mitigate the cytokine release syndrome by decreasing cytokine concentrations and acute-phase reactant production [70]. |
| T450 | 529-648 | Sentence | denotes | In a recent preprint paper, Xu et al. [71] reported their experience of treating 21 COVID-19 patients with tocilizumab. |
| T451 | 649-1039 | Sentence | denotes | In their still-to-be-peer-reviewed case series, the following were observed after tocilizumab administration: (a) reduction in body temperature (21/21, 100%); (b) improved blood oxygenation (15/21, 71.4%); (c) normalization of lymphocyte count (10/17, 58.8%); (d) normalization of C-reactive protein (16/19, 82.4%); and (c) resolution of abnormalities on computed tomography (19/21, 90.5%). |
| T452 | 1040-1166 | Sentence | denotes | Interestingly, no adverse reactions were observed after tocilizumab administration, but long-term follow-up was not available. |
| T453 | 1167-1325 | Sentence | denotes | Tocilizumab has been deemed by Chinese National Health Commission to be a possible treatment option for patients with severe COVID-19 with elevated IL-6 [72]. |
| T454 | 1326-1508 | Sentence | denotes | The recommended dose is 4 to 8 mg/kg or 400 mg standard dose provided intravenously once, with the option to repeat a dose after 8 to 12 hours (not to exceed a total dose of 800 mg). |
| T455 | 1509-1706 | Sentence | denotes | However, it should be noted that the optimal time for administering tocilizumab has not yet been fully elucidated; nor is there a clear IL-6 threshold associated with progression to severe disease. |
| T456 | 1707-1849 | Sentence | denotes | At the time of writing, there are at least eight ongoing RCT evaluating the efficacy and safety of tocilizumab in COVID-19 patients (Table 2). |
2_test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 32360444-24834925-22369811 | 113-115 | 24834925 | denotes | 68 |
| 32360444-24834925-22369812 | 365-367 | 24834925 | denotes | 68 |
| 32360444-18358927-22369813 | 368-370 | 18358927 | denotes | 69 |